This clinical trial studies the effectiveness of targeted anti-cancer drugs in patients with advanced cancer. The study aims to evaluate how well different medications work in treating cancers that have specific molecular profiles. The medications being tested include pemigatinib, trastuzumab, pertuzumab, vismodegib, apalutamide, abemaciclib, trametinib, atezolizumab, dabrafenib, entrectinib, olaparib, alectinib, regorafenib, vemurafenib, and tepotinib.
The study involves patients whose cancers have specific genetic changes that can be targeted by these medications. Before starting treatment, patients must undergo molecular testing of their tumor to determine if they have genetic changes that might make the treatment effective. This testing may include various methods such as fluorescence in situ hybridization, polymerase chain reaction, next generation sequencing, or immunohistochemistry.
The main goal is to measure how well patients respond to treatment after 16 weeks. Researchers will track how long the treatment works, monitor side effects, measure tumor response, and evaluate how long patients survive without their cancer getting worse. The study will also look at overall survival rates. Treatment will continue as long as patients are benefiting from it and not experiencing unacceptable side effects.
Finland 
